机器人抗菌药物敏感性平台(RASP):One Health 耐药监测的新一代方法
研究开发了符合 CLSI 和 ISO 20776-1:2019 标准的机器人高通量抗菌药物敏感性监测平台 RASP,并通过三项实验验证其性能。实验 A 显示 RASP 与人工技师在四种大肠埃希菌分离株的八次重复中 MIC 结果一致,偏差在一个倍比稀释内;实验 B 在 91 株大肠埃希菌中显示机器人与人工 MIC 的一致性相关系数为 0.9670(95%CI:0.9670-0.9670);应用于五份粪便样本时,每份样本鉴定出五至九种独特的大肠埃希菌耐药表型。结论认为 RASP 在通量、成本和数据分辨率上优于人工技师,是未来 One Health 耐药监测的必要进步。
要点
- RASP 在四种大肠埃希菌的八次重复中与人工 MIC 结果一致,偏差在一个倍比稀释内。
- 在 91 株大肠埃希菌中,机器人与人工 MIC 的一致性相关系数为 0.9670(95%CI:0.9670-0.9670)。
- 五份粪便样本中每份鉴定出五至九种独特的大肠埃希菌耐药表型。
核心结论
- RASP 在通量、成本和数据分辨率上优于经验丰富的人工技师,是未来 One Health 耐药监测的必要进步。
研究设计与样本
- 研究开发了符合 CLSI 和 ISO 20776-1:2019 标准的机器人高通量 AMR 监测平台 RASP,并通过实验 A、实验 B 和实际样本应用进行验证。
- 实验 A 比较 RASP 与人工技师在四种大肠埃希菌分离株八次重复中达到一致 MIC 的能力。
- 实验 B 评估 RASP 与人工 MIC 在 91 株具有多样 AMR 谱的大肠埃希菌中的一致性。
- RASP 工作流程应用于五份粪便样本,每份样本至少评估 47 株大肠埃希菌(共 239 株),使用 AMR 索引框架。
主要发现
- 实验 A 中每个药物-评分者-分离株组合的 MIC 存在明确共识,偏离共识在一个倍比稀释内(庆大霉素两个稀释除外)。
- 实验 B 中机器人与人工 MIC 的一致性相关系数为 0.9670(95%CI:0.9670-0.9670)。
- 五份粪便样本中每份鉴定出五至九种独特的大肠埃希菌耐药表型,显示动物内肠道共生大肠埃希菌的多样性。
关键数值与推荐
- RASP 遵循 CLSI 和 ISO 20776-1:2019 国际标准。
- 实验 A 中四个大肠埃希菌分离株、八次重复,每个药物-评分者-分离株组合 MIC 偏离共识在一个倍比稀释内(庆大霉素两个稀释除外)。
- 实验 B 中 91 株大肠埃希菌,机器人与人工 MIC 一致性相关系数 0.9670(95%CI:0.9670-0.9670)。
- 五份粪便样本每份至少 47 株大肠埃希菌(共 239 株),每份鉴定出五至九种独特耐药表型。
临床怎么用
- RASP 可作为高通量 AMR 监测工具,在微生物实验室中整合机器人平台以提升通量、降低成本并提高数据分辨率。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Surveillance of antimicrobial resistance (AMR) is critical to reducing its wide-reaching impact. Its reliance on sample size invites solutions to longstanding constraints regarding scalability. A robotic platform (RASP) was developed for high-throughput AMR surveillance in accordance with internationally recognized standards (CLSI and ISO 20776-1:2019) and validated through a series of experiments. METHODS: Experiment A compared RASP's ability to achieve consistent MICs with that of a human technician across eight replicates for four Escherichia coli isolates. Experiment B assessed RASP's agreement with human-performed MICs across 91 E. coli isolates with a diverse range of AMR profiles. Additionally, to demonstrate its real-world applicability, the RASP workflow was then applied to five faecal samples where a minimum of 47 E. coli per animal (239 total) were evaluated using an AMR indexing framework. RESULTS: For each drug-rater-isolate combination in Experiment A, there was a clear consensus of the MIC and deviation from the consensus remained within one doubling dilution (the exception being gentamicin at two dilutions). Experiment B revealed a concordance correlation coefficient of 0.9670 (95% CI: 0.9670-0.9670) between the robot- and human-performed MICs. RASP's application to the five faecal samples highlighted the intra-animal diversity of gut commensal E. coli, identifying between five and nine unique isolate AMR phenotypes per sample. CONCLUSIONS: While adhering to internationally accepted guidelines, RASP was superior in throughput, cost and data resolution when compared with an experienced human technician. Integration of robotics platforms in the microbiology laboratory is a necessary advancement for future One Health AMR endeavours.
引用
- Truswell A, Abraham R, O'Dea M, et al. Robotic Antimicrobial Susceptibility Platform (RASP): a next-generation approach to One Health surveillance of antimicrobial resistance. J Antimicrob Chemother. 2021. PMID: 33893498. doi:10.1093/jac/dkab107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。